Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab + ECX in locally advanced gastric cancer
NCT01234324Phase 2Completed
- Sponsor
- AIO-Studien
- Start
- Oct 2010
- Primary completion
- Aug 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of panitumumab in gastric cancer (GC) and gastroesophageal junction cancer (2 arms), sponsored by AIO-Studien. Primary endpoint: Frequency of pT3/T4 categories after surgery at 9 weeks. Started Oct 2010; status: completed.
02
Drugs
panitumumab
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT01234324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01234324.